{"disease":{"id":"virus-disease","name":"virus disease"},"drugs":{"marketed":[{"drug_id":"nirsevimab","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beyfortus","generic_name":"NIRSEVIMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"RSV","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":10,"revenue":"800","mechanism":"BEYFORTUS is a monoclonal antibody that targets RSV."},{"drug_id":"maftivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"MAFTIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":"76","mechanism":"Inmazeb works by binding to and neutralizing the Ebola virus."},{"drug_id":"atoltivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"ATOLTIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A","drug_class":"","quality_score":59,"revenue":"76","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells and thereby reducing the severity of the disease."},{"drug_id":"odesivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"ODESIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A","drug_class":"","quality_score":55,"revenue":"76","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells."},{"drug_id":"beyfortus","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beyfortus","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"nirsevimab-alip","indication_name":"Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BEYFORTUS","generic_name":"NIRSEVIMAB-ALIP","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Fusion glycoprotein F0","drug_class":"Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"inmazeb","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Inmazeb","company_name":"ANRS, Emerging Infectious Diseases","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"ansuvimab-zykl","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EBANGA","generic_name":"ANSUVIMAB-ZYKL","company_name":"RIDGEBACK BIOTHERAPEUTICS","drug_phase":"marketed","molecular_target":"Envelope glycoprotein","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"rsv-prefusion-f-protein-based-vaccine","indication_name":"Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSV prefusion F protein-based vaccine","generic_name":"rsv-prefusion-f-protein-based-vaccine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Respiratory syncytial virus fusion (F) protein","drug_class":"Viral protein subunit vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Coronavirus Disease 2019 (COVID-19)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"ansuvimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ebov Mab114","generic_name":"ANSUVIMAB","company_name":"Ridgeback Biotherapeutics","drug_phase":"marketed","molecular_target":"","drug_class":"Zaire Ebolavirus Glycoprotein-directed Antibody","quality_score":10,"revenue":null,"mechanism":"Ansuvimab works by binding to the Ebola virus glycoprotein, preventing the virus from entering host cells."},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05321433","title":"Tobacco Use and the Risk of COVID-19 and Adverse Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":757585,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05606198","title":"Post-COVID-19 Monitoring in Routine Health Insurance Data With Focus on Autoimmune Diseases (POINTED-AD)","phase":"","overall_status":"COMPLETED","enrollment_count":641407,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT05074953","title":"Post-COVID-19 Monitoring in Routine Health Insurance Data","phase":"","overall_status":"COMPLETED","enrollment_count":157134,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT07072793","title":"A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe","phase":"","overall_status":"COMPLETED","enrollment_count":131005,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03294473","title":"Centralized Reminder Recall - Flu RCT2","phase":"NA","overall_status":"COMPLETED","enrollment_count":70190,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05615792","title":"Observational Cohort of COVID-19 Patients in Hubei Province","phase":"","overall_status":"COMPLETED","enrollment_count":68000,"lead_sponsor_name":"Dao Wen Wang","has_results":false},{"nct_id":"NCT04908683","title":"A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25236,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04152486","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20426,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03739112","title":"Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12794,"lead_sponsor_name":"Medicago","has_results":true},{"nct_id":"NCT04346264","title":"CoVid-19 - Infection and Antibody Formation in the Viennese Population","phase":"","overall_status":"COMPLETED","enrollment_count":12419,"lead_sponsor_name":"Ludwig Boltzmann Institute for Lung Health","has_results":false},{"nct_id":"NCT03301051","title":"Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":10160,"lead_sponsor_name":"Medicago","has_results":true},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT04633603","title":"LázBarát™ (FeverFriend™) Projekt: Attitude Toward Fever and Its Change in the Healthcare System","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of Pecs","has_results":false},{"nct_id":"NCT04979208","title":"Impact of Changes in the Use of Care and Reorganization of the Healthcare System Linked to the Covid-19 Outbreak on the Quality of Care Pathways of Patients Suffering From Acute Myocardial Infarction and Stroke in Aquitaine (AVICOVID)","phase":"","overall_status":"COMPLETED","enrollment_count":9218,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04941144","title":"Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination","phase":"","overall_status":"COMPLETED","enrollment_count":8538,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05097677","title":"Follow-up of Covid-19 Long Term Sequelae","phase":"","overall_status":"COMPLETED","enrollment_count":7599,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Integrata Verona","has_results":false},{"nct_id":"NCT04694495","title":"HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study","phase":"","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT04327206","title":"BCG Vaccination to Protect Healthcare Workers Against COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":6828,"lead_sponsor_name":"Murdoch Childrens Research Institute","has_results":false},{"nct_id":"NCT04367740","title":"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":6313,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT04610515","title":"Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT04627623","title":"Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration","phase":"","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Medical University of Silesia","has_results":false},{"nct_id":"NCT03982199","title":"A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5815,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05244356","title":"Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation","phase":"NA","overall_status":"COMPLETED","enrollment_count":5784,"lead_sponsor_name":"Clinical Research Centre, Malaysia","has_results":false},{"nct_id":"NCT04375761","title":"COVID-19: Human Epidemiology and Response to SARS-CoV-2","phase":"","overall_status":"COMPLETED","enrollment_count":5599,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04545047","title":"Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":5044,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT07445763","title":"TARSILA Real-World Evidence Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inova Medical","has_results":false},{"nct_id":"NCT03098862","title":"PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response","phase":"","overall_status":"COMPLETED","enrollment_count":4830,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02876328","title":"Partnership for Research on Ebola VACcinations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4789,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05569408","title":"eVusheld Assessment reaL wORld Effectiveness in DoD Health System","phase":"","overall_status":"COMPLETED","enrollment_count":4724,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05594147","title":"An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib","phase":"","overall_status":"COMPLETED","enrollment_count":4103,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02431923","title":"Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":4043,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04348214","title":"Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals","phase":"","overall_status":"COMPLETED","enrollment_count":4040,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT07358117","title":"Viral Infections of the Central Nervous System: Diagnosis and Clinical Outcome","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT05722665","title":"Convolutional Neural Network Model to Detect Coronavirus Disease 2019 (COVID-19) Pneumonia in Chest Radiographs","phase":"","overall_status":"COMPLETED","enrollment_count":3599,"lead_sponsor_name":"Fundacion Clinica Valle del Lili","has_results":false},{"nct_id":"NCT05453006","title":"HPV Self-Sampling in Somali Women (Isbaar Project)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3367,"lead_sponsor_name":"University of Minnesota","has_results":true},{"nct_id":"NCT06667700","title":"A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3082,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05913700","title":"Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3067,"lead_sponsor_name":"Institute for Clinical Effectiveness, Japan","has_results":false},{"nct_id":"NCT02485301","title":"A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3024,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04377724","title":"Spread and Course of COVID-19 Infections","phase":"","overall_status":"COMPLETED","enrollment_count":2910,"lead_sponsor_name":"Goldhahn Jörg","has_results":false},{"nct_id":"NCT01340937","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2808,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06821061","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":2650,"lead_sponsor_name":"BioNTech SE","has_results":false},{"nct_id":"NCT05534074","title":"University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"University Hospital, Ioannina","has_results":false},{"nct_id":"NCT04939428","title":"Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2441,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03110770","title":"VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2428,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04074928","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2414,"lead_sponsor_name":"Seqirus","has_results":true},{"nct_id":"NCT03158233","title":"Zika Case Definition and Surveillance Study","phase":"","overall_status":"COMPLETED","enrollment_count":2400,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT05330832","title":"Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers (CoViTro-I)","phase":"","overall_status":"UNKNOWN","enrollment_count":2200,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT03072030","title":"International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT05787431","title":"Levels of Physical Activity After SARS-CoV-2 Infection in Pre-illness Vaccinated and Unvaccinated Greek Adults.","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Emmanouil D. Zacharakis","has_results":false},{"nct_id":"NCT04403100","title":"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: \"The Hope Coalition - 1\"","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1968,"lead_sponsor_name":"Cardresearch","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}